DOW JONES26,957.59-123.77 -0.46%
S&P 5003,116.39-11.82 -0.38%
NASDAQ8,980.78+15.16 0.17%

UPDATE: Mizuho Initiates Coverage On Pfizer with Buy Rating, Announces $42 Price Target As Firm Sees 'products such as Eliquis, Xtandi, and Xeljanz helping "New Pfizer" drive 7%+ sales and 9%+ income CAGR from 2020-2025.'

Benzinga · 02/06/2020 16:11